Safety/tolerability of the anti-semaphorin 4D Antibody VX15/2503 in a randomized phase 1 trial

Cite this paper

@inproceedings{LaGanke2017SafetytolerabilityOT, title={Safety/tolerability of the anti-semaphorin 4D Antibody VX15/2503 in a randomized phase 1 trial}, author={Christopher C. LaGanke and Lawrence M Samkoff and Keith R. Edwards and Lily K Jung Henson and Pavle Repovic and Sharon G. Lynch and Lael Stone and David H. Mattson and Aaron Galluzzi and Terrence L. Fisher and Christine Anne Reilly and Laurie A. Winter and John E. Leonard and Maurice Zauderer}, booktitle={Neurology(R) neuroimmunology & neuroinflammation}, year={2017} }